A House Energy and Commerce Health Subcommittee hearing on June 11, 2009 will focus on a new Federal Trade Commission (FTC) report titled "Emerging Health Care Issues: Follow-on Biologic Drug Competition." The report will describe findings from an FTC nvestigation into the effects of a follow-on biologics pathway on competition and innovation. In particular, the report will address whether additional incentives, beyond those provided by patents and pricing, are needed to ensure continued innovation in the biologics market.